The endothelial mineralocorticoid receptor: Mediator of the switch from vascular health to disease

Current Opinion in Nephrology and Hypertension

Volumn 26, Issue 2, 2017, Pages 97-104

  Davel, Ana P ^a,b   Anwar, Imran J ^a   Jaffe, Iris Z ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

cardiovascular disease; endothelial function; mineralocorticoid receptor

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL SODIUM CHANNEL; MINERALOCORTICOID RECEPTOR; NITRIC OXIDE;

ARTERIAL STIFFNESS; BLOOD VESSEL FUNCTION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; THROMBOSIS; VASCULITIS; ANIMAL; CARDIOVASCULAR DISEASE; INFLAMMATION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; INFLAMMATION; NITRIC OXIDE; OXIDATIVE STRESS; RECEPTORS, MINERALOCORTICOID; RISK FACTORS; SIGNAL TRANSDUCTION; VASCULAR STIFFNESS;

EID: 85002489719     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000306     Document Type: Review

References (53)

1. Félétou M, Köhler R, Vanhoutte PM. Endothelium-derived vasoactive factors and hypertension: possible roles in pathogenesis and as treatment targets. Curr Hypertens Rep 2010; 12:267-275.
2. Daiber A, Steven S, Weber A, et al. Targeting vascular (endothelial) dysfunction. Br J Pharmacol 2016. [Epub ahead of print]
3. Lother A, Hein L. Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease. Hypertension 2016; 68:6-10.
4. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioac-tivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101:594-597.
5. Thum T, Schmitter K, Fleissner F, et al. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. Eur Heart J 2011; 32:1275-1286.
6. Garg R, Rao AD, Baimas-George M, et al. Mineralocorticoid receptor block-ade improves coronary microvascular function in individuals with type 2 diabetes. Diabetes 2015; 64:236-242.
7. Caprio M, Newfell BG, la Sala A, et al. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 2008; 102:1359-1367.
8. McCurley A, Jaffe IZ. Mineralocorticoid receptors in vascular function and disease. Mol Cell Endocrinol 2012; 350:256-265.
9. Briones AM, Nguyen Dinh Cat A, Callera GE, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 2012; 59:1069-1078.
10. Victorio JA, Clerici SP, Palacios R, et al. Spironolactone prevents endothelial nitric oxide synthase uncoupling and vascular dysfunction Induced by b-adrenergic overstimulation: role of perivascular adipose tissue. Hypertension 2016; 68:726-735.
11. Moss ME, Jaffe IZ. Mineralocorticoid receptors in the pathophysiology of vascular inflammation and atherosclerosis. Front Endocrinol (Lausanne) 2015; 6:153.
12. Skøtt O, Uhrenholt TR, Schjerning J, et al. Rapid actions of aldosterone in vascular health and disease - friend or foe? Pharmacol Ther 2006; 111:495-507.
13. Uhrenholt TR, Schjerning J, Hansen PB, et al. Rapid inhibition of vasocon-striction in renal afferent arterioles by aldosterone. Circ Res 2003; 93:1258-1266.
14. Nagata D, Takahashi M, Sawai K, et al. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension 2006; 48:165-171.
15. Leopold JA, Dam A, Maron BA, et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13:189-197.
16. Mutoh A, Isshiki M, Fujita T. Aldosterone enhances ligand-stimulated nitric oxide production in endothelial cells. Hypertens Res 2008; 31:1811-1820.
17. Nietlispach F, Julius B, Schindler R, et al. Influence of acute and chronic mineralocorticoid excess on endothelial function in healthy men. Hypertension 2007; 50:82-88.
18. Hwang MH, Yoo JK, Luttrell M, et al. Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults. Exp Gerontol 2016; 73:86-94.
19. Hwang MH, Yoo JK, Luttrell M, et al. Mineralocorticoid receptors modulate vascular endothelial function in human obesity. Clin Sci (Lond) 2013; 125:513-520.
20. Chen L, Ding ML, Wu F, et al. Impaired endothelial repair capacity of early endothelial progenitor cells in hypertensive patients with primary hyperaldos-teronemia: role of 5,6,7,8-tetrahydrobiopterin oxidation and endothelial nitric oxide synthase uncoupling. Hypertension 2016; 67:430-439.
21. Schäfer N, Lohmann C, Winnik S, et al. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity. Eur Heart J 2013; 34:3515-3524.
22. Rickard AJ, Morgan J, Chrissobolis S, et al. Endothelial cell mineralocorticoid receptors regulate deoxycorticosterone/salt-mediated cardiac remodeling and vascular reactivity but not blood pressure. Hypertension 2014; 63:1033-1040.
23. Dinh QN, Young MJ, Evans MA, et al. Aldosterone-induced oxidative stress and inflammation in the brain are mediated by the endothelial cell miner-alocorticoid receptor. Brain Res 2016; 1637:146-153.
24. Mueller KB, Bender SB, Hong K, et al. Endothelial mineralocorticoid receptors differentially contribute to coronary and mesenteric vascular function without modulating blood pressure. Hypertension 2015; 66:988-997.
25. Jia G, Habibi J, Aroor AR, et al. Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females. Circ Res 2016; 118:935-943.
26. Jia G, Habibi J, DeMarco VG, et al. Endothelial mineralocorticoid receptor deletion prevents diet-induced cardiac diastolic dysfunction in females. Hypertension 2015; 66:1159-1167.
27. Lagrange J, Li Z, Fassot C, et al. Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. FASEB J 2014; 28:2062-2072.
28. Nguyen Dinh Cat A, Griol-Charhbili V, Loufrani L, et al. The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB J 2010; 24:2454-2463.
29. Bene NC, Alcaide P, Wortis HH, Jaffe IZ. Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease. Steroids 2014; 91:38-45.
30. Bentley-Lewis R, Adler GK, Perlstein T, et al. Body mass index predicts aldosterone production in normotensive adults on a high-salt diet. J Clin Endocrinol Metab 2007; 92:4472-4475.
31. Huby AC, Antonova G, Groenendyk J, et al. Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation 2015; 132:2134-2145.
32. Jia G, Aroor AR, Martinez-Lemus LA, Sowers JR. Overnutrition, mTOR signaling, and cardiovascular diseases. Am J Physiol Regul Integr Comp Physiol 2014; 307:R1198-1206.
33. Caroccia B, Seccia TM, Campos AG, et al. GPER-1 and estrogen receptor-b ligands modulate aldosterone synthesis. Endocrinology 2014; 155:4296-4304.
34. Huby AC, Otvos L, Belin de Chantemèle EJ. Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice. Hypertension 2016; 67:1020-1028.
35. Barrett Mueller K, Lu Q, Mohammad NN, et al. Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology 2014; 155:4461-4472.
36. Toda N, Nakanishi S, Tanabe S. Aldosterone affects blood flow and vascular tone regulated by endothelium-derived NO: therapeutic implications. Br J Pharmacol 2013; 168:519-533.
37. Mohandas A, Suboc TB, Wang J, et al. Mineralocorticoid exposure and receptor activity modulate microvascular endothelial function in African Americans with and without hypertension. Vasc Med 2015; 20:401-408.
38. Davies JI, Band M, Morris A, Struthers AD. Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004; 47:1687-1694.
39. Swaminathan K, Davies J, George J, et al. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia 2008; 51:762-768.
40. Hwang MH, Yoo JK, Luttrell M, et al. Effect of selective mineralocorticoid receptor blockade on flow-mediated dilation and insulin resistance in older adults with metabolic syndrome. Metab Syndr Relat Disord 2015; 13:356-361.
41. Sudano I, Naegele M, Roas S, et al. Vascular effects of eplerenone in coronary artery disease with preserved ejection fraction: a double-blind, randomized, placebo-controlled trial. Clin Cardiol 2016; 39:285-290.
42. DeMarco VG, Habibi J, Jia G, et al. Low-dose mineralocorticoid receptor blockade prevents western diet-induced arterial stiffening in female mice. Hypertension 2015; 66:99-107.
43. Silva MA, Bruder-Nascimento T, Cau SB, et al. Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling. Front Physiol 2015; 6:269.
44. Kratz MT, Schirmer SH, Baumhäkel M, Böhm M. Improvement of endothelial function in a murine model of mild cholesterol-induced atherosclerosis by mineralocorticoid antagonism. Atherosclerosis 2016; 251:291-298.
45. DuPont JJ, Hill MA, Bender SB, et al. Aldosterone and vascular mineralo-corticoid receptors: regulators of ion channels beyond the kidney. Hypertension 2014; 63:632-637.
46. Kusche-Vihrog K, Sobczak K, Bangel N, et al. Aldosterone and amiloride alter ENaC abundance in vascular endothelium. Pflugers Arch 2008; 455:849-857.
47. Drüppel V, Kusche-Vihrog K, Grossmann C, et al. Long-term application of the aldosterone antagonist spironolactone prevents stiff endothelial cell syndrome. FASEB J 2013; 27:3652-3659.
48. Kusche-Vihrog K, Jeggle P, Oberleithner H. The role of ENaC in vascular endothelium. Pflugers Arch 2014; 466:851-859.
49. Bodary PF, Sambaziotis C, Wickenheiser KJ, et al. Aldosterone promotes thrombosis formation after arterial injury in mice. Arterioscler Thromb Vasc Biol 2006; 26:233.
50. Gromotowicz A, Szemraj J, Stankiewicz A, et al. Study of the mechanisms of aldosterone prothrombotic effect in rats. J Renin Angiotensin Aldosterone Syst 2011; 12:430-439.
51. Salvador AM, Nevers T, Velázquez F, et al. Intercellular adhesion molecule 1 regulates left ventricular leukocyte infiltration, cardiac remodeling, and function in pressure overload-induced heart failure. J Am Heart Assoc 2016; 5:e003126.
52. Lother A, Fürst D, Bergemann S, et al. Deoxycorticosterone acetate/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorti-coid receptors independently from blood pressure. Hypertension 2016; 67:130-138.
53. Manrique C, Lastra G, Ramirez-Perez FI, et al. Endothelial estrogen receptor-a does not protect against vascular stiffness induced by western diet in female mice. Endocrinology 2016; 157:1590-1600.